Free Trial
NASDAQ:LRMR

Larimar Therapeutics Q2 2025 Earnings Report

Larimar Therapeutics logo
$3.38 -1.71 (-33.60%)
Closing price 04:00 PM Eastern
Extended Trading
$3.38 0.00 (0.00%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Larimar Therapeutics EPS Results

Actual EPS
-$0.41
Consensus EPS
-$0.47
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

Larimar Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Larimar Therapeutics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Thursday, August 14, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Larimar Therapeutics' Q3 2025 earnings is scheduled for Wednesday, October 29, 2025, with a conference call scheduled on Thursday, October 30, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Larimar Therapeutics Earnings Headlines

Early Activity. Real Signal.
A repeatable signal just triggered—one we’ve seen before major moves. This time, it’s pointing to a small-cap flying under nearly everyone’s radar. Daily Edge Report just released a free alert with full details, including the company name and why this setup stands out.tc pixel
Larimar Therapeutics, Inc. - Special Call
See More Larimar Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Larimar Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Larimar Therapeutics and other key companies, straight to your email.

About Larimar Therapeutics

Larimar Therapeutics (NASDAQ:LRMR), a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

View Larimar Therapeutics Profile

More Earnings Resources from MarketBeat